B · Normal
[Novo Nordisk: Novo Nordisk® approved for patent term compensation for chronic kidney disease indications] On November 10, Novo Nordisk announced today that the drug patent term extension (Patent Term Extension) of its patents related to the chronic kidney disease (CKD) indication of Novota® (semaglutide injection) has been approved by the State Intellectual Property Office, and the patent protection period for related indications has been extended by 5 years to March 2031.
Innovative drugs 🕐 2026-11-10 13:37
#Innovative drugs
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Four departments: Local health administration departments are not allowed to li 11-10 12:39 [Four departments: Individual discussion on supporting independent declaration o 11-10 12:38 [Four departments issued a document: Strengthening the safe and rational deploym 11-10 12:30 [The concept of innovative drugs rebounded with shock and Laimi Pharmaceutical r 11-09 09:57 [The concept of innovative drugs has surged, and Haichuang Pharmaceutical has ri 11-05 09:33 [The concept of innovative drugs continues to rise, WuXi AppTec closes the daily 11-04 14:10

Comments

0/500
Captcha (click to refresh)
No comments yet